Protocol summary
-
Study aim
-
Determination of the effect of probiotic capsule on metabolic parameters, oxidative stress and clinical signs of age-related macular degeneration (AMD), 1397 in Kashan
-
Design
-
This study will be designed as a clinical trial.Double-blind control-placebo is performed on 70 patients with ARMD in the range of 50-85 years old. First, patients are identified based on biochemical findings and a fundoscopic finding with ARMD history.Then they are treated with one of the treatment groups or placebo
-
Settings and conduct
-
This clinical trial is performed on 70 individuals with age-related macular degeneration which referred to Kashan Matini Hospital.Individuals based on random Blocks (one per group) will be divided to probotic or placebo capsule,one per day for 2 months. Individuals checked by the phone monthly and at the beginning and end of the study they will have a visit and blood tests and clinical examinations will be done for them. All drug are presented in the same package and the physician , patients, researcher and statistical analyst are blind .After analyzing data, codes will be decoded.
-
Participants/Inclusion and exclusion criteria
-
Entrance criteria: aged 50 to 85 years, diminished vision solely due to AMD
Exit criteria: corneal opacity, diabetes, history of retinal vascular disorders, history of retina tear, history of penetrating trauma
-
Intervention groups
-
Intervention group: probiotic capsule 500 mg, produced in tak gene company, ,One number per day for 2
months orally. Control group: placebo capsule 500 Mg, produced in tak gene company, ,One number per day for 2 months orally.
-
Main outcome variables
-
Fasting blood glucose Plasma; Insulin Serum; Insulin resistance; Hs-CRP; Total glutathione; Macular thickness; Visual acuity
General information
-
Reason for update
-
Due to changes occur during the trial
-
Acronym
-
-
IRCT registration information
-
IRCT registration number:
IRCT20130211012438N30
Registration date:
2019-02-19, 1397/11/30
Registration timing:
retrospective
Last update:
2022-12-31, 1401/10/10
Update count:
1
-
Registration date
-
2019-02-19, 1397/11/30
-
Registrant information
-
-
Recruitment status
-
Recruitment complete
-
Funding source
-
-
Expected recruitment start date
-
2018-05-20, 1397/02/30
-
Expected recruitment end date
-
2018-11-21, 1397/08/30
-
Actual recruitment start date
-
2018-05-20, 1397/02/30
-
Actual recruitment end date
-
2018-11-21, 1397/08/30
-
Trial completion date
-
2019-01-20, 1397/10/30
-
Scientific title
-
Evaluation of the effects of capsules containing probiotics on metabolic parameters, oxidative stress and clinical symptoms of age-related macular degeneration
-
Public title
-
The effect of probiotic capsule on patients with macular degeneration associated with age
-
Purpose
-
Treatment
-
Inclusion/Exclusion criteria
-
Inclusion criteria:
Reduced vision simply because of AMD
Exclusion criteria:
Corneal opacity
Diabetes
History of retinal vascular disorders
History of retina tear
History of penetrating trauma
-
Age
-
From 50 years old to 85 years old
-
Gender
-
Both
-
Phase
-
3
-
Groups that have been masked
-
- Participant
- Care provider
- Investigator
- Outcome assessor
-
Sample size
-
Target sample size:
70
Actual sample size reached:
70
-
Randomization (investigator's opinion)
-
Randomized
-
Randomization description
-
Random Blocks (one per group): Patients will be divided into two groups, probiotic (case) and placebo (control ). The division of selected subjects will be done randomly in blocks of study using quadrilateral blocks. The division of selected subjects will be done in randomized blocks using six rows of four blocks (ABAB-BABA-ABBA-BAAB-AABB-BBAA). probiotic capsule (A) and placebo group (B). In this way, different scenarios are written on six cards and will be thrown into a bag and 60 cards will be written out of the bag for 15 times, and the order will be written in a sheet.
-
Blinding (investigator's opinion)
-
Double blinded
-
Blinding description
-
Drugs and placebo are in the same packaging at the Barij Essence pharmaceutical company . Only the code is written on the packages. Patients and physician do not know the type of drug and after analyzing the data, packet codes are decoded.
-
Placebo
-
Used
-
Assignment
-
Parallel
-
Other design features
-
Ethics committees
1
-
Ethics committee
-
-
Approval date
-
2017-12-11, 1396/09/20
-
Ethics committee reference number
-
IR.KAUMS.NUHEPM.REC.1396.16
Health conditions studied
1
-
Description of health condition studied
-
Age-related macular degeneration
-
ICD-10 code
-
H35.3
-
ICD-10 code description
-
Degeneration of macula and posterior pole
Primary outcomes
1
-
Description
-
High sensitive-Critical Reactive Protein
-
Timepoint
-
At the beginning of the study and2 months after the start of the study
-
Method of measurement
-
ELISA
Secondary outcomes
1
-
Description
-
Visual Acuity
-
Timepoint
-
At the beginning of the study and 2 months after the start of the study
-
Method of measurement
-
Visual Acuity check with Snellen chart
2
-
Description
-
Macular thickness
-
Timepoint
-
At the beginning of the study and 2 months after the start of the study
-
Method of measurement
-
Central Macular Thickness Evaluate with OCT Instrument
3
-
Description
-
Fasting plasma glucose
-
Timepoint
-
At the beginning of the study and 2 months after the start of the study
-
Method of measurement
-
Enzymatic Kits
4
-
Description
-
Triglycerides
-
Timepoint
-
At the beginning of the study and 2 months after the start of the study
-
Method of measurement
-
Enzymatic Kits
5
-
Description
-
Low density lipoprotein-cholesterol
-
Timepoint
-
At the beginning of the study and 2 months after the start of the study
-
Method of measurement
-
Enzymatic Kits
6
-
Description
-
High density lipoprotein-cholesterol
-
Timepoint
-
At the beginning of the study and 2 months after the start of the study
-
Method of measurement
-
Enzymatic Kits
7
-
Description
-
Total cholesterol
-
Timepoint
-
At the beginning of the study and 2 months after the start of the study
-
Method of measurement
-
Enzymatic Kits
8
-
Description
-
Very low density lipoprotein-cholesterol
-
Timepoint
-
At the beginning of the study and 2 months after the start of the study
-
Method of measurement
-
Standard formula
9
-
Description
-
Nitric oxide
-
Timepoint
-
At the beginning of the study and 2 months after the start of the study
-
Method of measurement
-
Photospectrometry
10
-
Description
-
Malondialdehyde
-
Timepoint
-
At the beginning of the study and 2 months after the start of the study
-
Method of measurement
-
Photospectrometry
11
-
Description
-
Glutathion
-
Timepoint
-
At the beginning of the study and 2 months after the start of the study
-
Method of measurement
-
Photospectrometry
12
-
Description
-
Total Anti Oxidant
-
Timepoint
-
At the beginning of the study and 2 months after the start of the study
-
Method of measurement
-
Photospectrometry
13
-
Description
-
Insulin
-
Timepoint
-
At the beginning of the study and 2 months after the start of the study
-
Method of measurement
-
ELISA
14
-
Description
-
QUICKI
-
Timepoint
-
At the beginning of the study and 2 months after the start of the study
-
Method of measurement
-
Standard formula
15
-
Description
-
HOMA-IR
-
Timepoint
-
At the beginning of the study and 2 months after the start of the study
-
Method of measurement
-
Standard formula
Intervention groups
1
-
Description
-
Intervention group: probiotic capsule 500 MG,produced in tak gene company,One number per day for 2 months orally.
-
Category
-
Treatment - Drugs
2
-
Description
-
Control group: placebo capsule500 MG, produced in Tak gene company, ,One number per day for 2 months orally.
-
Category
-
Placebo
1
-
Sponsor
-
-
Grant name
-
-
Grant code / Reference number
-
-
Is the source of funding the same sponsor organization/entity?
-
Yes
-
Title of funding source
-
Kashan University of Medical Sciences
-
Proportion provided by this source
-
100
-
Public or private sector
-
Public
-
Domestic or foreign origin
-
Domestic
-
Category of foreign source of funding
-
empty
-
Country of origin
-
-
Type of organization providing the funding
-
Academic
Sharing plan
-
Deidentified Individual Participant Data Set (IPD)
-
Undecided - It is not yet known if there will be a plan to make this available
-
Study Protocol
-
Undecided - It is not yet known if there will be a plan to make this available
-
Statistical Analysis Plan
-
Undecided - It is not yet known if there will be a plan to make this available
-
Informed Consent Form
-
Undecided - It is not yet known if there will be a plan to make this available
-
Clinical Study Report
-
Undecided - It is not yet known if there will be a plan to make this available
-
Analytic Code
-
Undecided - It is not yet known if there will be a plan to make this available
-
Data Dictionary
-
Undecided - It is not yet known if there will be a plan to make this available